<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1289">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790685</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00079951</org_study_id>
    <nct_id>NCT01790685</nct_id>
  </id_info>
  <brief_title>Ozurdex for Retinal Vein Occlusion Study (ORVO Study)</brief_title>
  <acronym>ORVO</acronym>
  <official_title>Ozurdex for Retinal Vein Occlusion Study (ORVO Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To measure the pro-permeability factors in the aqueous humor of patients with
      persistent/recurrent macular edema after an injection of Ozurdex.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To measure various pro-permeability factors in the aqueous humor of patients with
      persistent/recurrent macular edema despite prior treatment with anti-VEGF agents at baseline
      and at 4 weeks after intraocular injection of OZURDEX.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants Who Had a &gt;30% Decrease in the Aqueous Levels of Various Vasoactive Proteins 4 Weeks After an Injection of Ozurdex</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vasoactive protein arrays and Enzyme linked immunosorbent assays were done for patients at baseline and week 4 visit to measure the levels of various pro-permeability factors including VEGF, SDF-1 and Angiopoietin-2.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>CRVO</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Central Retinal Vein Occlusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BRVO</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Branch Retinal Vein Occlusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone implant</intervention_name>
    <arm_group_label>CRVO</arm_group_label>
    <arm_group_label>BRVO</arm_group_label>
    <other_name>Ozurdex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent and authorization of use and disclosure of protected health
             information

          -  Age more than or equal to 18 years

          -  Diagnosis of macular edema due to central or branch retinal vein occlusion

          -  Intraretinal or subretinal fluid in the macula determined by Spectralis OCT

          -  Best corrected visual acuity score in the study eye of 20/30 to 20/400 inclusive
             (Snellen equivalents using the ETDRS protocol at a distance of 4 meters)

          -  In the opinion of the investigator, decreased vision in the study eye is due to
             foveal thickening from vein occlusion and not from other obvious causes of decreased
             vision

          -  Persistent or recurrent edema despite prolonged treatment with an anti-VEFG agent

        Exclusion Criteria:

          -  Scatter laser photocoagulation or macular photocoagulation within 3 months of study
             entry in the study eye

          -  Intraocular surgery in the study eye within 3 months of study entry

          -  Use of intraocular or periocular injection of steroids in the study eye (e.g.,
             triamcinolone) within 4 months of study entry

          -  Previous use of an anti-VEGF drug within 1 month of study entry

          -  Yttrium-Aluminum-Garnet (YAG) laser capsulotomy within 1 month of study entry

          -  Any condition that the investigator believes would pose a significant hazard to the
             subject if investigational therapy were initiated.

          -  Inability to comply with study or follow up procedures

          -  History of glaucoma or documented history of steroid-induced glaucoma.

          -  Patients with active or suspected ocular or periocular infection, including most
             viral diseases of the cornea and conjunctiva, including active epithelial herpes
             simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial
             infections, and fungal diseases.

          -  Aphakic eyes with rupture of the posterior lens capsule.

          -  Eyes with ACIOL and rupture of the posterior lens capsule.

          -  Patients with hypersensitivity to dexamethasone or to any other components of the
             product
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 2, 2015</lastchanged_date>
  <firstreceived_date>February 8, 2013</firstreceived_date>
  <firstreceived_results_date>January 7, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Peter A Campochiaro, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>40 patients from the clinic population of the Wilmer Eye Institute were recruited,</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>CRVO</title>
          <description>Central Retinal Vein Occlusion
dexamethasone implant</description>
        </group>
        <group group_id="P2">
          <title>BRVO</title>
          <description>Branch Retinal Vein Occlusion
dexamethasone implant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CRVO</title>
          <description>Central Retinal Vein Occlusion
dexamethasone implant</description>
        </group>
        <group group_id="B2">
          <title>BRVO</title>
          <description>Branch Retinal Vein Occlusion
dexamethasone implant</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="74" lower_limit="54" upper_limit="90"/>
                <measurement group_id="B2" value="72" lower_limit="54" upper_limit="89"/>
                <measurement group_id="B3" value="73" lower_limit="54" upper_limit="90"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="16"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had a &gt;30% Decrease in the Aqueous Levels of Various Vasoactive Proteins 4 Weeks After an Injection of Ozurdex</title>
        <description>Vasoactive protein arrays and Enzyme linked immunosorbent assays were done for patients at baseline and week 4 visit to measure the levels of various pro-permeability factors including VEGF, SDF-1 and Angiopoietin-2.</description>
        <time_frame>4 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All enrolled (23 CRVO and 17 BRVO) patients completed the study. All patients were injected with Ozurdex, however microarrays were run on only 11 CRVO and 17 BRVO patient samples. Microarray data from 11 CRVO and 11 BRVO patients was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>CRVO</title>
            <description>Central Retinal Vein Occlusion
dexamethasone implant</description>
          </group>
          <group group_id="O2">
            <title>BRVO</title>
            <description>Branch Retinal Vein Occlusion
dexamethasone implant</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Had a &gt;30% Decrease in the Aqueous Levels of Various Vasoactive Proteins 4 Weeks After an Injection of Ozurdex</title>
            <description>Vasoactive protein arrays and Enzyme linked immunosorbent assays were done for patients at baseline and week 4 visit to measure the levels of various pro-permeability factors including VEGF, SDF-1 and Angiopoietin-2.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>HGF</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EG-VEGF</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Activin-A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IGFBP-1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IGFBP-2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IGF-BP3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Endostatin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CRVO</title>
          <description>Central Retinal Vein Occlusion
dexamethasone implant</description>
        </group>
        <group group_id="E2">
          <title>BRVO</title>
          <description>Branch Retinal Vein Occlusion
dexamethasone implant</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>The patient was hospitalized for stomach pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>The patient was hospitalized for an infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Patient fell down the stairs and was hospitalized for a cerebral bleed.</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Patient fell and hit head on the back of a chair resulting in trauma and infection in the study eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in IOP in study eye</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Redness of study eye after drug injection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Patient had an uneventful fall</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is a restriction on the PI regarding disclosure of study results, which will be updated once the manuscript is published.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Peter A. Campochiaro</name_or_title>
      <organization>Johns Hopkins</organization>
      <phone>410-955-5106</phone>
      <email>pcampo@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
